SG11202010237RA - Fusion protein binding to cd47 protein and application thereof - Google Patents
Fusion protein binding to cd47 protein and application thereofInfo
- Publication number
- SG11202010237RA SG11202010237RA SG11202010237RA SG11202010237RA SG11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- application
- binding
- fusion protein
- fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810343482.9A CN110386984B (zh) | 2018-04-17 | 2018-04-17 | 结合cd47蛋白的融合蛋白及其应用 |
PCT/CN2019/082863 WO2019201236A1 (zh) | 2018-04-17 | 2019-04-16 | 结合cd47蛋白的融合蛋白及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010237RA true SG11202010237RA (en) | 2020-11-27 |
Family
ID=68239336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010237RA SG11202010237RA (en) | 2018-04-17 | 2019-04-16 | Fusion protein binding to cd47 protein and application thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US11891423B2 (zh) |
EP (1) | EP3795595A4 (zh) |
JP (1) | JP2021520830A (zh) |
KR (1) | KR20210003766A (zh) |
CN (2) | CN110386984B (zh) |
AU (1) | AU2019256177A1 (zh) |
BR (1) | BR112020021294A2 (zh) |
CA (1) | CA3097417A1 (zh) |
SG (1) | SG11202010237RA (zh) |
TW (1) | TWI822760B (zh) |
WO (1) | WO2019201236A1 (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021011544A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
CN111253482B (zh) * | 2020-02-18 | 2021-11-30 | 中国人民解放军军事科学院军事医学研究院 | SIRPa变体、融合蛋白、及其应用 |
CN111808183B (zh) * | 2020-07-25 | 2022-07-08 | 北京吉尔麦迪生物医药科技有限公司 | 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白 |
KR102398032B1 (ko) * | 2020-09-22 | 2022-05-19 | 비피진 주식회사 | 암 치료를 위한 5''-뉴클레오티다아제 변이체 |
CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
KR20230105583A (ko) * | 2022-01-04 | 2023-07-11 | 비피진 주식회사 | 5'-뉴클레오티다아제 변형 단백질을 암호화하는 암 치료를 위한 폴리뉴클레오티드 |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201100947A1 (ru) | 2008-12-19 | 2012-02-28 | Новартис Аг | Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений |
WO2010130053A1 (en) * | 2009-05-15 | 2010-11-18 | University Health Network | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION |
DK2931752T3 (da) * | 2012-12-17 | 2019-11-18 | Trillium Therapeutics Inc | Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner |
WO2015066550A1 (en) * | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
ES2751915T5 (es) * | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
CN108350048B (zh) * | 2015-08-07 | 2024-02-09 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
WO2018014068A1 (en) * | 2016-07-19 | 2018-01-25 | Teva Pharmaceuticals Australia Pty Ltd | Attenuated type i ifn cd47 combination therapy |
PL3658589T3 (pl) * | 2017-07-26 | 2024-03-18 | Forty Seven, Inc. | Przeciwciała anty-sirp-alfa i powiązane sposoby |
-
2018
- 2018-04-17 CN CN201810343482.9A patent/CN110386984B/zh active Active
-
2019
- 2019-04-16 BR BR112020021294-6A patent/BR112020021294A2/pt unknown
- 2019-04-16 EP EP19789512.1A patent/EP3795595A4/en active Pending
- 2019-04-16 AU AU2019256177A patent/AU2019256177A1/en active Pending
- 2019-04-16 WO PCT/CN2019/082863 patent/WO2019201236A1/zh unknown
- 2019-04-16 KR KR1020207031110A patent/KR20210003766A/ko not_active Application Discontinuation
- 2019-04-16 SG SG11202010237RA patent/SG11202010237RA/en unknown
- 2019-04-16 US US17/048,202 patent/US11891423B2/en active Active
- 2019-04-16 CN CN201980026165.7A patent/CN111989346A/zh active Pending
- 2019-04-16 JP JP2020556859A patent/JP2021520830A/ja active Pending
- 2019-04-16 CA CA3097417A patent/CA3097417A1/en active Pending
- 2019-04-16 TW TW108113225A patent/TWI822760B/zh active
Also Published As
Publication number | Publication date |
---|---|
BR112020021294A2 (pt) | 2021-01-26 |
US20210171593A1 (en) | 2021-06-10 |
JP2021520830A (ja) | 2021-08-26 |
CN111989346A (zh) | 2020-11-24 |
US11891423B2 (en) | 2024-02-06 |
EP3795595A4 (en) | 2022-03-16 |
KR20210003766A (ko) | 2021-01-12 |
CN110386984A (zh) | 2019-10-29 |
CN110386984B (zh) | 2022-04-22 |
EP3795595A1 (en) | 2021-03-24 |
WO2019201236A1 (zh) | 2019-10-24 |
TWI822760B (zh) | 2023-11-21 |
CA3097417A1 (en) | 2019-10-24 |
TW201943728A (zh) | 2019-11-16 |
AU2019256177A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202010237RA (en) | Fusion protein binding to cd47 protein and application thereof | |
IL268258A (en) | CD47 antigen binding unit and uses thereof | |
EP3612218A4 (en) | ANTI-TREM2 ANTIGEN BINDING PROTEINS AND THEIR USES | |
IL265489B (en) | Recombinant binding proteins and their uses | |
IL278943A (en) | Multi-specificity binding proteins and improvements thereof | |
EP3544628A4 (en) | 4-1BB BINDING PROTEINS AND THEIR USES | |
GB201709537D0 (en) | Fusion protein comprising three binding domains to 5ta and cd3 | |
EP3275895A4 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
EP3613771A4 (en) | FOR LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE OF IT | |
EP3290441A4 (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
HK1253533A1 (zh) | Cd131結合蛋白及其應用 | |
IL284679A (en) | Multifunctional chimeric proteins and their use | |
EP3722305A4 (en) | HM-3 FUSION PROTEIN AND USES THEREOF | |
IL278102A (en) | Fusion proteins containing cd47 antibodies and cytokines | |
IL275248A (en) | Fusion protein of a therapeutic enzyme with a new structure and its use | |
SG11202110400QA (en) | Fusion protein and use thereof | |
EP3445394A4 (en) | ALK7 BINDING PROTEINS AND USES THEREOF | |
EP3836959A4 (en) | ANTI-ANGIOGENESIS FUSION PROTEIN AND USES ITS | |
EP3668551A4 (en) | APOM FC FUSION PROTEINS AND USES THEREOF | |
EP4041772A4 (en) | 4-1BB-BINDING ANTIBODIES AND USES THEREOF | |
SG11202104912SA (en) | Fusion protein and use thereof | |
IL290715A (en) | nkg2d fusion proteins and their use | |
EP3805265A4 (en) | ANTIBODIES BINDING TO TIE2 AND USES THEREOF | |
EP3816181A4 (en) | IMPROVED FVIII FUSION PROTEIN AND ITS USE | |
EP3700571A4 (en) | ALK7-BINDING PROTEINS AND USES THEREOF |